Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives

• Published in: International journal of molecular sciences Vol. 21; no. 13; p. 4579
• Main Authors: Cocco, Stefania, Piezzo, Michela, Calabrese, Alessandra, Cianniello, Daniela, Caputo, Roberta, Lauro, Vincenzo Di, Fusco, Giuseppina, Gioia, Germira di, Licenziato, Marina, De Laurentiis, Michelino
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 27.06.2020; MDPI
• Subjects: Animals; Biomarkers; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; BRCA1/2; Breast cancer; Breast Neoplasms - diagnosis; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Chemotherapy; Female; Gene expression; Gene Expression Regulation, Neoplastic; HRR; Humans; Mutation; Ovarian cancer; Patients; PDL1; PI3KCA; Prognosis; Review; Subgroups; TILs; TNBC; Tumors; United States > US; BRCA1/2; CSC; PTEN; HRR; TILs; PDL1; TNBC; CTCs; PI3KCA
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms21134579

Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors characterized by aggressive behavior, high risk of distant recurrence, and poor survival. Chemotherapy is still the main therapeutic approach for this subgroup of patients, therefore, progress in the treatment of TNBC remains an important challenge. Data derived from molecular technologies have identified TNBCs with different gene expression and mutation profiles that may help developing targeted therapies. So far, however, only a few of these have shown to improve the prognosis and outcomes of TNBC patients. Robust predictive biomarkers to accelerate clinical progress are needed. Herein, we review prognostic and predictive biomarkers in TNBC, discuss the current evidence supporting their use, and look at the future of this research field.